Biologics for pediatric atopic dermatitis A protocol of A systematic review and meta - analysis
Abstract Background Atopic dermatitis is a common chronic pruritic inflammatory skin disease, tends to occur in children. The objective of this study is to evaluate the treatment of pediatric atopic dermatitis with Biologics, as biologics continue to emerge for atopic dermatitis (AD)Methods The databases we will search include Embase, Cochrane Library, Web of Science, the and PubMed of RCTs from inception to 15st May 2022. The primary outcomes The proportion of patients with EASI 75 as the primary outcome,. The secondary outcomes incloud NRS, DLQI score and adverse reaction incidence.Studies will be screened by two independent authors. They will assess the risk of bias of the final included studies according to the RCTs bias risk evaluation tool in Cochrane System Review Manual 5.1.0. Meta-analysis will be performed using RevMan 5.3 software.Results The research results will provide a reference for the clinical application of biological agents in pediatric atopic dermatitis.Conclusion We aims to evaluate the efficacy and safety of biologics in pediatric atopic dermatitis and provide evidence-based data for clinical applicationEthics and dissemination The study does not collect raw data and personal information, does not involve jeopardizing the rights of the participants. Ethical approval was not required. The results may be reported in publications and the mediaPROSPERO registration number CRD42022319052(<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/PROSPERO/#joinuppage">https://www.crd.york.ac.uk/PROSPERO/#joinuppage</jats:ext-link>).
| Medienart: |
|
|---|
Preprint| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
bioRxiv.org - (2024) vom: 23. Apr. Zur Gesamtaufnahme - year:2024 |
|---|
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Cao, Rui [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| doi: |
10.1101/2022.07.07.22277362 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
XBI036477370 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | XBI036477370 | ||
| 003 | DE-627 | ||
| 005 | 20240424105332.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220710s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1101/2022.07.07.22277362 |2 doi | |
| 035 | |a (DE-627)XBI036477370 | ||
| 035 | |a (biorXiv)10.1101/2022.07.07.22277362 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Cao, Rui |e verfasserin |0 (orcid)0000-0002-8730-0908 |4 aut | |
| 245 | 1 | 0 | |a Biologics for pediatric atopic dermatitis A protocol of A systematic review and meta - analysis |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Abstract Background Atopic dermatitis is a common chronic pruritic inflammatory skin disease, tends to occur in children. The objective of this study is to evaluate the treatment of pediatric atopic dermatitis with Biologics, as biologics continue to emerge for atopic dermatitis (AD)Methods The databases we will search include Embase, Cochrane Library, Web of Science, the and PubMed of RCTs from inception to 15st May 2022. The primary outcomes The proportion of patients with EASI 75 as the primary outcome,. The secondary outcomes incloud NRS, DLQI score and adverse reaction incidence.Studies will be screened by two independent authors. They will assess the risk of bias of the final included studies according to the RCTs bias risk evaluation tool in Cochrane System Review Manual 5.1.0. Meta-analysis will be performed using RevMan 5.3 software.Results The research results will provide a reference for the clinical application of biological agents in pediatric atopic dermatitis.Conclusion We aims to evaluate the efficacy and safety of biologics in pediatric atopic dermatitis and provide evidence-based data for clinical applicationEthics and dissemination The study does not collect raw data and personal information, does not involve jeopardizing the rights of the participants. Ethical approval was not required. The results may be reported in publications and the mediaPROSPERO registration number CRD42022319052(<jats:ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.crd.york.ac.uk/PROSPERO/#joinuppage">https://www.crd.york.ac.uk/PROSPERO/#joinuppage</jats:ext-link>) | ||
| 650 | 4 | |a Biology |7 (dpeaa)DE-84 | |
| 650 | 4 | |a 570 |7 (dpeaa)DE-84 | |
| 700 | 1 | |a Lu, Jiaxing |e verfasserin |4 aut | |
| 700 | 1 | |a Chen, Zhao |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t bioRxiv.org |g (2024) vom: 23. Apr. |
| 773 | 1 | 8 | |g year:2024 |g day:23 |g month:04 |
| 856 | 4 | 0 | |u https://doi.org/10.1371/journal.pone.0271712 |x 0 |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1101/2022.07.07.22277362 |x 0 |z kostenfrei |3 Volltext |
| 912 | |a GBV_XBI | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 23 |c 04 | ||